Skip to main content

Table 4 Univariable and Multivariable Cox Proportional Hazards for prediction of progression in the well-balanced cohort

From: Symptomatic venous thromboembolism associated with peripherally inserted central catheters predicts a worse survival in nasopharyngeal carcinoma: results of a large cohort, propensity score–matched analysis

Predictors

Univariable analysis

Multivariable analysis

HR (95% CI)

p value

HR (95% CI)

p value

Gender

 Female

1.00 (ref.)

Not included

 

 Male

1.40 (0.94, 2.07)

0.095

  

Age,yr

 ≤ 45

1.00 (ref.)

1.00 (ref.)

 > 45

1.42 (1.03, 1.96)

0.032

1.49 (1.07, 2.06)

0.017

ECOG scale

 0–1

1.00 (ref.)

Not included

 

 2

0.92 (0.13, 6.58)

0.935

  

Smoking

 No

1.00 (ref.)

Not included

 

 Yes

1.18 (0.86, 1.64)

0.309

  

NPC family history

 No

1.00 (ref.)

Not included

 

 Yes

0.96 (0.58, 1.59)

0.882

  

Tumor stage

 1

1.00 (ref.)

1.00 (ref.)

 2

1.61 (0.46, 5.64)

0.460

0.89 (0.24, 3.23)

0.856

 3

1.65 (0.52, 5.25)

0.400

0.97 (0.29, 3.31)

0.966

 4

3.32 (1.05, 10.52)

0.041

1.25 (0.36, 4.30)

0.729

Node stage

 0

1.00 (ref.)

Not included

 

 1

1.12 (0.54, 2.29)

0.764

  

 2

1.11 (0.55, 2.24)

0.767

  

 3

1.54 (0.75, 3.18)

0.240

  

UICC clinical stage

 2

1.00 (ref.)

1.00 (ref.)

 3

3.72 (0.51, 26.98)

0.194

3.66 (0.50, 26.65)

0.200

 4

8.68 (1.21, 62.16)

0.032

7.56 (1.05, 54.55)

0.045

Radiotherapy

 2DRT

1.00 (ref.)

Not included

 

 IMRT

1.14 (0.16, 8.13)

0.898

  

BMI, kg/m2

 < 18.5

1.00 (ref.)

1.00 (ref.)

 18.5–23.9

0.63 (0.38, 1.03)

0.066

0.64 (0.38, 1.06)

0.080

 24–27.9

0.68 (0.40, 1.15)

0.150

0.79 (0.46, 1.35)

0.384

 ≥ 28

0.31 (0.12, 0.77)

0.012

0.35 (0.14, 0.88)

0.025

EBVDNA, copy/mL

 ≤ 4000

1.00 (ref.)

1.00 (ref.)

 > 4000

2.27 (1.63, 3.16)

< 0.001

2.07 (1.47, 2.91)

< 0.001

HGB, g/L

 < 113

1.00 (ref.)

Not included

 

 113–151

3.09 (0.76, 12.52)

0.114

  

 ≥ 151

2.70 (0.66, 11.08)

0.169

  

hs-CRP, g/mL

 < 1.0

1.00 (ref.)

1.00 (ref.)

 1.0–3.0

0.92 (0.60, 1.41)

0.689

0.76 (0.49, 1.17)

0.210

 ≥ 3.0

1.53 (1.03, 2.27)

0.036

1.20 (0.80, 1.80)

0.375

LDH, U/L

 < 245

1.00 (ref.)

Not included

 

 ≥ 245

1.58 (0.97, 2.59)

0.066

  

PICC-VTE

 No

1.00 (ref.)

1.00 (ref.)

 Yes

2.79 (1.97, 3.96)

< 0.001

2.92 (2.06, 4.15)

< 0.001

  1. Abbreviations: 2DRT Two-dimensional radiotherapy, EBV Epstein-Barr virus, ECOG Eastern Cooperative Oncology Group, hs-CRP high-sensitivity C-reactive protein, IMRT Intensity-modulated radiotherapy, LDH Serum lactate dehydrogenase levels, HGB Hemoglobin, NPC Nasopharyngeal carcinoma, UICC Union for International Cancer Control, BMI Body Mass Index, PICC Peripherally Inserted Central Catheter, VTE Venous thromboembolism, ref. reference, CI Confidence intervals